T HE PROCESSES OF successful pregnancy include embryo implantation, placentation, and local immune suppression for maternal tolerance to fetal foreign antigens. Maternal oxygen and nutrient supply via an extensive vascular network of endometrium to placenta are indispensable for fetal growth. However, the relevant molecular mechanisms of neovascularization of endometrium and placenta are still obscure. A number of growth factors, cytokines, and phospholipids may exert modulatory effects. These include vascular endothelial growth factor (VEGF), IL-8, IL-6, angiopoietin-1 and -2, angiogenin, human chorionic gonadotropin (hCG), prostaglandins, and platelet-activating factor (1) (2) (3) (4) (5) (6) (7) (8) (9) .
An increase in serum lysophospholipase D activity had been found during pregnancy in human (10) . It was suggested that lysophosphatidic acid (LPA) formed by increased activity of lysophospholipase D might participate in maintenance of pregnancy. LPA, a biologically active phospholipid, plays critical roles in physiological and pathological processes including inflammation, cell proliferation, angiogenesis, wound healing, and cancer invasion (11) (12) (13) (14) (15) . LPA could be produced through the hydrolysis of phospholipids by extracellular lysophospholipase D (10) or activated platelets, leukocytes, epithelial cells, and tumor cells (16 -18) . However, the physiological roles of increased LPA during pregnancy remain unclear.
LPA exhibits pleiotropic functions via the interaction with specific G protein (Go, Gs, Gi, or G12/13)-coupled endothelial differentiation gene (Edg) receptors including LPA1/ Edg2, LPA2/Edg4, or LPA3/Edg7 (19) . In humans, whereas the expression of the LPA receptors has been reported in some healthy tissues and cancer cells (13, 20) , the expression of the LPA receptor isoforms in the endometrium is unknown. Recently LPA was demonstrated to promote ovarian cancer growth by inducing angiogenic factors including VEGF, IL-6, and IL-8 through various LPA receptors (21) (22) (23) . The relation between LPA and increased angiogenic factors in pregnancy merits further investigation.
In the present study, we attempted to determine the possible role of LPA in pregnancy. We first examined the LPA
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receptors of endometrial stromal cells. The effects of LPA on endometrial stromal cells regarding expressions of angiogenic factors of VEGF, IL-6, or IL-8 were examined, and the signaling pathways were investigated. We then explored whether LPA-induced angiogenic factors modified migration, permeability, capillary tube formation, or proliferation of human endometrial microvascular endothelial cells (hEMVECs).
Materials and Methods

Endometrial tissues
Endometrial specimens were obtained from 38 premenopausal women (aged 35-44 yr) undergoing hysterectomy for leiomyoma. Decidua or placenta specimens were obtained from 12 women receiving elective termination of pregnancy (7-10 wk). This study was approved by the Ethics Committee of National Taiwan University Hospital, and informed consent was obtained from patients. The phases of endometrium were determined by histological criteria. The dispersed endometrial cells were separated by filtration through a 40-m nylon cell strainer (Becton Dickinson, Franklin Lakes, NJ). Endometrial stromal cells in the filtrate were cultured in phenol-red-free DMEM/F-12 containing 10% charcoal-stripped fetal bovine serum. The purity of endometrial stromal cells was more than 99%, as determined by staining with antibodies to vimentin and cytokeratin.
Antibodies and reagents
Pertussis toxin (PTX), Ki16425, AG1478, LY294002, PD98059, SB203580, 1-oleoyl-LPA, and fatty acid-free BSA were purchased from Sigma-Aldrich (St. Louis, MO). LPA was dissolved in vehicle of PBS containing 1% fatty acid-free BSA. Recombinant human IL-8 and IL-8 neutralizing antibodies were obtained from R&D Systems (Minneapolis, MN). Antibodies to human p38 and phospho-p38 were from Santa Cruz Biotechnology (Santa Cruz, CA).
Flow cytometry analysis
Endometrial stromal cells were incubated with anti-LPA1, LPA2, or LPA3 antibodies (1:100 dilutions; BD PharMingen, San Diego, CA) for 60 min. Isotype antibodies were used for background controls. Using fluorescein isothiocyanate-labeled secondary antibody, the cell surface expression of LPA1, LPA2, or LPA3 receptor was analyzed by flow cytometry (BD Biosciences, San Jose, CA).
RT-PCR
The total RNA was isolated from the endometrial stromal cells using the RNAzol B reagent (Biotecx Laboratories, Houston, TX). Then cDNA was prepared from 2 g of the total RNA with random hexamer primers (ImProm-II RT system; Promega, Southampton, UK). The specific oligonucleotide primer pairs for LPA receptors were as follows: LPA1, 5Ј-CAA AAT GAG GCC TTA CGA CGC CA-3Ј and 5Ј-TCC CAT TCT GAA GTG CTG CGT TC-3Ј; LPA2, 5Ј-GCG CGC GGA TCC ACC ATG GTC ATC ATG GGC CAG TGC-3Ј and 5Ј-GCG CGG TCG ACT CAG TCC TGT TGG TTG GGT TGA-3Ј; LPA3, 5Ј-CTG ATG TTT AAC ACA GGC CC-3Ј and 5Ј-GAC GTT GGT TTT CCT CTT GA-3Ј (12) .
Immunohistochemistry (IHC)
The formalin-fixed and paraffin-embedded endometrial or placental tissues were used for IHC. Sections were incubated with anti-LPA1 or anti-IL-8 antibodies (Santa Cruz Biotechnology) for 60 min. Then the sections were incubated with biotinylated secondary antibody. The localization of LPA1 receptors or IL-8 was detected using a streptavidinbiotin immunoperoxidase kit (Dako Ltd., Buckinghamshire, UK).
Enzyme immunoassay (EIA)
Endometrial stromal cells were plated into 6-well culture plates at a density of 2 ϫ 10 5 cells/well. After cell attachment, cell layers were washed and incubated with serum-free medium for 24 h. The cells were then treated with either vehicle or indicated conditions. After 24 h, the supernatant were collected. Levels of IL-6, IL-8, and VEGF were determined using EIA kits (R&D Systems).
RNA interference
Small interfering RNA (siRNA) duplexes were purchased from Santa Cruz Biotechnology. The targeted siRNA of LPA1 was sc-43746. Endometrial stromal cells were transfected with siRNA at the concentration of 25 nm in serum-free Opti-MEM by using the Oligofectamine method (Invitrogen Corp., Carlsbad, CA).
Real-time quantitative RT-PCR
We quantified IL-8 mRNA expression in various conditions using a fluorescein quantitative real-time PCR detection system (Light Cycler DNA master SYBR Green I; Roche Molecular Biochemicals, Indianapolis, IN). The primer pairs were: 5Ј-TTT CTG CAG CTC TCT GTG AGG-3Ј and 5Ј-CTG CTG TTG TTG TTG CTT CTC-3Ј for IL-8; 5Ј-GGG AAG GTG AAG GTC GG-3Ј and 5Ј-TGG ACT CCA CGA CGT ACT CAG-3Ј for glyceraldehyde-3-phosphate dehydrogenase. Amplification was followed by melting curve analysis to verify the correctness of the amplicon. The amount of IL-8 mRNA was normalized by that of glyceraldehyde-3-phosphate dehydrogenase mRNA and is presented in arbitrary units, with 1 U corresponding to the value in cells treated with a vehicle control.
Promoter construction and reporter assays
Transfections of plasmid of human IL8 -1.4 Kb or nuclear factor-B (NF-B) binding site-driven luciferase plasmids (BD Bioscience) into endometrial stromal cells was performed using the Transfast transfection reagent (Promega). At 24 h after transfection, cells were serum starved for 24 h and then treated with the indicated conditions.
Western blotting
The endometrial stromal cell lysates were centrifuged at 12,000 rpm for 25 min at 4 C. The protein concentration then was measured using a Bio-Rad protein assay (Hercules, CA). A 50-g protein sample was separated using SDS-PAGE, transferred onto polyvinylidene difluoride membrane, and immunoblotted with various antibodies.
NF-B and activator protein-1 (AP-1) decoy oligodeoxynucleotides to endometrial stromal cells
The sequences of the phosphorothioate oligodeoxynucleotides of NF-B decoy, AP-1 decoy, or scrambled decoys had been described previously (20) . The oligodeoxynucleotides was mixed with the Transfast transfection reagent (Promega) for 15 min and then incubated with the endometrial stromal cells in a serum-free medium.
hEMVEC migration assay hEMVECs were separated from fresh first trimester decidua. The endometrial specimen was homogenized and resuspended in 1 ml of cold M199 medium containing 0.3 mg/ml magnetic tosyl-activated M-450 Dynabeads (Dynal, Oslo, Norway), which had been coated with mouse antihuman CD31. The endothelial cells bound to the magnetic beads were isolated using a MPC-1 magnet (Dynal) and were cultured in endothelial cell culture medium (Sigma-Aldrich).
hEMVEC migration was measured using the in vitro wound healing assay. hEMVECs were grown to confluence on 12-well culture dishes. Wounds were made with an approximate width of 110 m using a sterile blunt glass bar. The medium was changed to indicate conditions. After 6 h, the hEMVECs were fixed with 1% formaldehyde and stained with 0.05% crystal violet. The distances of wounds were measured and photographed.
hEMVEC monolayer permeability assay hEMVEC were cultured in trans-well chambers (0.4 m pore-size polycarbonate filters; Costar Corp., Cambridge, MA). After reaching confluence, the medium was replaced with the indicated conditions (0.3 ml in the upper chamber and 1 ml in the lower chamber). Horseradish peroxidase molecules (type VI-A, 44 kDa; Sigma-Aldrich) at a concentration of 0.126 m were added to the upper compartment. After incubation for 1 h, the medium in the lower compartment was assayed for enzymatic activity using a photometric guaiacol substrate assay (Sigma-Aldrich).
hEMVEC capillary tube formation assay hEMVECs (5 ϫ 10 4 ) in the medium of indicated conditions were plated on a growth factor-reduced Matrigel (BD Biosciences, Franklin Lakes, NJ)-coated 24-well plates. After incubation for 6 h, the wells were examined for tube formation under a phase-contrast microscope.
hEMVEC proliferation assay hEMVECs were seeded in 96-well plates at densities of 1 ϫ 10 4 cells/well using 0.2 ml of endothelial cell medium. After 24 h for cell attachment, the medium was changed to the indicated conditions. After incubation for 72 h, the number of hEMVECs was analyzed using the trypan blue exclusion assay.
Statistics
In this study, each experiment was repeated at least three times on different occasions. Data were presented as mean Ϯ sd. The data were examined with one-way ANOVA, followed by Tukey test for multiple comparisons. Significance level was set as P Ͻ 0.05 by two-tailed test.
SAS software version 8.01 (SAS Institute Inc., Cary, NC) was used for calculation.
Results
LPA1 receptors are expressed in human endometrial stromal cells
We first detected LPA receptors with specific LPA1, LPA2, and LPA3 antibodies in primary culture of endometrial stromal cells by flow cytometry. The cells incubated with LPA1-specific antibody displayed a significant area shift, whereas those with LPA2 or LPA3 did not exhibit this change (Fig.  1A) . The quantitative data from nine cases revealed that LPA1 receptors were highly expressed in endometrial stromal cells (Fig. 1B) . No differences of LPA1 expressions were found among the proliferative phase, secretory phase and first-trimester endometrium.
We further confirmed expression patterns of LPA receptors by RT-PCR. Those were compared with SK-OV3 cell line, which was a well-known ovarian cancer cell line with expressions of LPA1, LPA2, and LPA3 receptors. The results indicated that only LPA1 receptors' mRNA was expressed in endometrial stromal cells of the proliferative and secretory phases as well as first-trimester decidua (Fig. 1C) . The IHC results further demonstrated that LPA1 receptors located in the stromal cells and glandular epithelium of human endometrium as well as in the endothelial cells (Fig. 2, A-C) . In addition, IL-8 was also present in the endometrium (Fig. 2 , D and E). 
LPA enhances IL-8 expression in endometrial stromal cells at both protein and mRNA levels
Via the primary culture system, LPA was applied to the endometrial stromal cells of the secretory phase and first-trimester decidua. Using EIA, we found that LPA significantly increased IL-8 protein secretion (8.9 Ϯ 1.2-and 8.7 Ϯ 1.1-fold, respectively) at 24 h and also at 48 and 72 h. However, LPA did not enhance IL-6 or VEGF secretions (Fig. 3A) . The hCG did not obviously increase VEGF secretion at 24 h but significantly increased it at 48 and 72 h. In contrast, hCG did not induce IL-8 or IL-6 secretions (Fig. 3B) .
We examined the dosage effect of LPA on IL-8 secretion (Fig. 3C) . The results revealed that upon stimulation of LPA, the secretion of IL-8 was enhanced in a dose-dependent manner from 1 to 20 m. Using real-time quantitative RT-PCR (Fig. 3D) , we found that mRNA expression of IL-8 increased in a time-dependent manner when treated with LPA. After the 8 h of treatment, the level of IL-8 (6.7 Ϯ 0.6-fold, compared with controls) reached the maximum.
Signal transduction pathway involved in LPA-induced IL-8 expression
We investigated the role of LPA receptor in LPA-induced IL-8 expression in endometrial stromal cells. Using EIA (Fig.  4A) , we found that both the Ki16425, an antagonist of LPA1 and LPA3, and PTX specifically abolished the LPA-enhanced IL-8 secretion. However, the epidermal growth factor receptor inhibitor (AG1478) did not diminish the enhancing effect. We further applied specific LPA1 receptor siRNA to affect mRNA expressions of LPA1 receptors (Fig. 4B, upper panel) . We found that the LPA1 siRNA significantly reduced LPAenhanced IL-8 secretion (Fig. 4B, lower panel) . These results indicated an involvement of the PTX-sensitive Gi proteincoupled LPA1 receptor, but not epidermal growth factor receptor, in the LPA-induced IL-8 expression in human endometrial stromal cells.
We further explored signal transduction mediators involved in LPA-induced IL-8 expression. Using EIA (Fig. 4C) , we verified that MAPK/p38 inhibitor (SB203580) significantly decreased LPA-enhanced IL-8 secretion but not phosphatidylinositol 3-kinase/Akt inhibitor (LY294002) or MAPK/ERK inhibitor (PD98059). Using Western blotting and densitometry (Fig. 4D) , we found that LPA strongly induced phosphorylation of p38. In addition, the phosphorylation was significantly diminished by pretreatments with Ki16425, PTX, or SB203580.
Because the upstream promoter sequences of IL-8 gene contain conserved putative binding sites for NF-B and AP-1, we used synthetic double-stranded oligodeoxynucleotides as decoy cis elements to examine the role of NF-B and AP-1 in LPA-induced IL-8 expression. We found that treatment with NF-B decoy, but not the AP-1 decoy, significantly decreased LPA-induced IL-8 promoter activity (Fig. 5A) . Using real-time quantitative RT-PCR, we also verified that LPAenhanced IL-8 mRNA expression was significantly diminished by NF-B decoy but not AP-1 decoy (Fig. 5B) . Using Western blotting and densitometry (Fig. 5C ), we observed that LPA induced NF-B nuclear translocation. The LPAenhanced NF-B nuclear translocation was decreased by inhibitors of Gi (PTX), p38 (SB203580), and NF-B (BAY117082). We further verified that LPA potently enhanced NF-B binding site-driven luciferase activity (12.0 Ϯ 1.7-fold), and the enhanced activity was significantly reduced by inhibitors of Gi (PTX), p38 (SB203580), and NF-B (BAY117082) (Fig. 5D) . These results indicated that NF-B played a critical role in LPA-induced IL-8 expression in human endometrial stromal cells.
LPA-induced IL-8 protein secretion from endometrial stromal cells enhances angiogenesis
Using in vitro wound healing assay (Fig. 6A, left panel) , we observed increased migration of hEMVECs when incubated (Fig. 6A,  right panel) .
With hEMVEC permeability assay ( In the test of hEMVEC capillary tube formation (Fig. 6C,  left panel Endometrial stromal cells were pretreated with PTX (100 ng/ml), SB203580 (50 g/ml), or BAY117082 (5 M) for 1 h before LPA treatment. Nuclear and cytosolic proteins were collected after 1 h. The levels of NF-B p65 subunits were examined by Western blotting. Data were measured as relative density of nuclear p65/cytosol p65. The nuclear p65/cytosol p65 of the vehicle control was defined as 1 (n ϭ 3). D, NF-B binding site-driven luciferase activity assay. Endometrial stromal cells were transfected with NF-B reporter plasmids. The cells were then pretreated with indicated chemical inhibitors for 1 h before stimulation with LPA. After 4 h, the NF-B binding site-driven luciferase activity was measured. Data are compared between the LPA-treated-only group and different inhibitor groups. *, P Ͻ 0.05 (n ϭ 5).
increase hEMVEC tube formation. On the contrary, LPAtreated CM preincubated with nonspecific IgG (e) or LPAtreated CM from cells pretreated with sense oligonucleotides (g) significantly augmented hEMVEC tube formation capability. Conversely, LPA-treated CM from cells pretreated with antisense IL-8 oligonucleotides added with rhIL-8 (h) or the rhIL-8-containing medium (i) significantly enhanced hEMVEC tube formation. The quantitative data indicated the specificity and direct effect of LPA-induced IL-8 in augmenting hEMVEC tube formation (Fig. 6C, right panel) .
In the examination of hEMVEC proliferation (Fig. 6D) The representation of LPA function through LPA1 receptors and signaling pathways in endometrial stromal cells was schematically summarized in Fig. 7 .
Discussion
In the present study, we first demonstrate that LPA1 receptors are expressed in human endometrial stromal cells in both the proliferative and secretory phases. In primary culture of endometrial stromal cells, LPA up-regulates IL-8 expression in a concentration-and time-dependent manner. We further prove that LPAinduced IL-8 protein functionally enhances multistep processes of angiogenesis including migration, permeability, capillary tube formation, and proliferation of endothelial cells. The process of implantation and pregnancy entails angiogenesis of endometrium and placenta. Increased concentration of LPA in pregnancy may mediate endometrial stromal cells to secrete IL-8 and regulate neovasculogenesis. Therefore, LPA may play a role in angiogenesis for the establishment of pregnancy.
The expression of hCG/LH receptors had been verified in human endometrium throughout the proliferative and secretory phases (24, 25) . Via its receptors to induce VEGF secretion, hCG was suggested to enhance angiogenesis of endometrium for promoting blastocyst implantation (7). IL-8 has been implicated in the involvement of normal menstruation, endometrial receptivity for embryonic implantation, and pregnancy (26) (27) (28) . The modulation of IL-8 secretion was found to be enhanced by other cytokines such as TNF-␣, IL-1␤, and thrombin in human first-trimester decidua cells (29) . Recently IL-8 mRNA expression was detected to be significantly induced by prokineticin 1 in human endometrium during early pregnancy (30) . Adiponectin decreased IL-1␤-induced secretion of IL-8 from endometrial stromal cells (31) . In this work, we demonstrated that LPA significantly induced IL-8 secretion but not VEGF in human endometrial stromal cells. On the contrary, hCG induced VEGF secretion but not IL-8. The LPAinduced IL-8 stimulated angiogenesis of endothelial cells in vitro.
Our results suggest that LPA may play a role in up-regulation of IL-8 during pregnancy.
We validate that through LPA1 receptors, the Gi protein, MAPK/p38, and NF-B pathway is involved in LPA-induced IL-8 expression in endometrial stromal cells. Recently LPA was found to induce IL-8 expression in bronchial epithelial cells (17) and human umbilical vein endothelial cells (32) as well as IL-8 and IL-6 expressions in dendritic cells (33) and granulosa-lutein cells (20) . These enhancement effects are also NF-B dependent (17, 20, 32 ). LPA appears to be an important physiological regulator for IL-8 or IL-6 secretions among human tissues.
In developmental studies of mice, LPA has been found to play important roles in embryo development and implantation. LPA enhanced the growth of two-or four-cell mouse embryos to blastocysts (34) and accelerated blastocyst outgrowth and differentiation (35, 36) . Mouse uteri expressed LPA3 receptors, and LPA may induce uterine cyclooxygenase-2 to enhance prostaglandins E 2 and I 2 generation (37) . Targeted deletion of the LPA3 receptor resulted in delayed implantation and altered embryo spacing and significantly reduced litter size. In humans, we first indicate that through LPA1 receptors, LPA induces IL-8 in endometrial stromal cells that may enhance angiogenesis of the endometrium and placenta.
In our previous study (20) , we found that granulosa-lutein cells expressed LPA1, LPA2, and LPA3 receptors. Through LPA receptors, LPA induced IL-8 and IL-6 secretions that IL-8 enhanced multisteps of angiogenesis of endothelial cells and IL-6 enhanced permeability. Ovarian cancer had been found to express LPA1, LPA2, and LPA3 receptors and to produce excessive LPA. LPA stimulated VEGF, IL-6, and IL-8 secretions in ovarian cancer and augmented tumor growth, angiogenesis, and invasion (14, (21) (22) (23) 38 ). It appears that in contrast to ovarian cancer inducing angiogenesis by LPA, the effect of LPA on physiological angiogenesis of endometrium and corpus luteum is mainly by IL-8 but not through VEGF.
LPA could be produced by extracellular lysophospholipase D or activated platelets, leukocytes, or epithelial cells. It had been found that serum lysophospholipase D activity increased during pregnancy (10) . High lysophospholipase activity was present in the human placental tissues and amnion (39) . However, the origin and local concentrations of LPA and its regulation by autocrine/ paracrine factors in the human uterine endometrium during the menstrual cycle and pregnancy remain unclear that deserve further investigation.
We demonstrate that LPA1 receptors are equally expressed in human endometrial stromal cells in the proliferative and secretory phases as well as first-trimester decidua. LPA induces IL-8 expression through the LPA1 receptor, Gi protein, MAPK/p38, and NF-B signal pathway. LPA-induced IL-8 protein stimulates migration, permeability, capillary tube formation, and proliferation of endothelial cells, which are critical steps involved in the angiogenesis. These results could suggest that LPA may play a role in angiogenesis of endometrium and placenta through induction of IL-8 in endometrial stromal cells during pregnancy.
